Monoclonal antibodies IPO-3 and IPO-10 against human B cell differentiation antigens.
Monoclonal antibodies (mAbs) IPO-3 and IPO-10 were generated following immunization of a BALB/c mice with human cell lines RPMI-1788 and Daudi respectively. The reactivity of these mAbs was studied by indirect immunofluorescence technique with 10 human cell lines, blood cells of healthy persons and patients with the malignant lymphoproliferative diseases. Studies of normal and neoplastic B cells suggest that mAbs IPO-3 and IPO-10 which recognize antigens are B lineage restricted. The presence of an antigen defined by the mAb IPO-10 appears to include most but not all the stages of B cell differentiation, whereas IPO-3 detected antigen is not represented on resting B cells and has a very limited expression on activated B lymphocytes. The results obtained with mAbs IPO-3 and IPO-10 are discussed in relation to other known B cell surface markers.
Pinchouk
V G
VG
R.E. Kavetsky Institute for Oncology Problems, Academy of Sciences, Ukrainian S.S.R., U.S.S.R.
Sidorenko
S P
SP
Gluzman
D F
DF
Vetrova
E P
EP
Berdova
A G
AG
Schlapatskaya
L N
LN
D000911:Antibodies, Monoclonal; D000944:Antigens, Differentiation, B-Lymphocyte / Q000032:analysis* / Q000276:immunology; D002460:Cell Line; D006801:Humans; D007244:Infectious Mononucleosis / Q000276:immunology; D007938:Leukemia / Q000276:immunology*; D008223:Lymphoma / Q000276:immunology*; D009000:Monocytes / Q000276:immunology; D009101:Multiple Myeloma / Q000276:immunology; D012016:Reference Values
D000911:Antibodies, Monoclonal; D000944:Antigens, Differentiation, B-Lymphocyte